ClinicalTrials.gg
RecruitingNCT07008391TIGERUpdated Jul 2, 2025

High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS

An interventional study of high sensitivity Troponin I in Emergency Medical Services, Nursing Care and Cardiology, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,419
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Myocardial Infarction by Karolinska Institutet — 2 open to participants now, 4 under way, none of them phase 3. Myocardial Infarction · Karolinska Institutet.

Planned enrollment
3rd of 12
1,419 · median 123
Started
2025
with 1 other
No phase
7 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Myocardial Infarction by Karolinska Institutet, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 with no phase, and was the 17th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

2 of the 17 studies in Myocardial Infarction by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myocardial Infarction by Karolinska Institutet, or all of them as a file.
02

Study summary

The TIGER study is a study investigating the utlility of a point-of-care blood analyse of Troponin I to help identify patients with heart attacks in the prehospital emergency care. The study is conducted within the ambulance services of Region Stockholm and compares standard medical care with and without the addition of this quick test.

Chest pain is one of the most common reasons for ambulance dispatch, but currently only about one-third of heart attacks are detected before arriving at the hospital-mainly through ECG. The remaining two-thirds are not identified until after further testing at the emergency department. The TIGER study aims to improve early diagnosis by using a high-sensitivity, point-of-care Troponin I test already in the prehospital phase.

The study is a randomized controlled trial, where participants are randomly assigned to one of two groups. One group receives standard emergency care along with the rapid Troponin I test in the ambulance. The other group receives standard care without the test. The goal is to evaluate whether the use of Troponin I testing leads to faster and more accurate identification of heart attacks, ultimately improving patient outcomes.

In total, about 1,419 adult patients with chest pain or suspected heart attack will participate. The primary outcome being measured is the time from first medical contact to PCI (balloon angioplasty). Secondary outcomes include time spent in different parts of care, hospital length of stay, the occurrence of serious events (such as heart attack, stroke, or death), and the diagnostic accuracy of the test.

The study has been approved by the Swedish Ethical Review Authority and includes safety monitoring through an interim analysis after the first 150 patients. Test results from the Troponin I analysis are clearly marked as part of the research study and should be interpreted by the responsible physician alongside other clinical findings.

Read the detailed description

The TIGER study is a prospective, open-label, randomized controlled trial designed to evaluate the clinical utility of prehospital high-sensitivity Troponin I testing in patients presenting with chest pain or suspected myocardial infarction (MI). The study is conducted within the emergency medical services (EMS) in Stockholm, Sweden.

Participants are randomized in a 2:1 ratio to receive either standard guideline-based care alone or standard care plus point-of-care Troponin I testing using the Siemens Atellica® VTLi system. The Troponin result is available to EMS providers in real-time and is communicated to the receiving hospital as part of the routine prehospital handover.

The study aims to assess whether the addition of early biomarker data can improve triage, reduce time to treatment (FMC-to-balloon time), and optimize the use of healthcare resources. An interim analysis will be conducted after 150 patients have been enrolled. The study has been approved by the Swedish Ethical Review Authority.

03

Conditions studied

  • Emergency Medical Services
  • Nursing Care
  • Cardiology
  • Myocardial Infarction
  • Myocardial Infarction or Chest Pain
  • Myocardial Infarction, Acute
  • Emergencies
  • Ambulance

Keywords

  • Ambulance
  • Prehospital emergency nurse
  • Sweden
  • Point-of-care
  • troponin
  • high sensitive troponin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chestpain / discomfort and/or
  • Clinical suspicion of myocardial infarction by the prehospital personeel

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from a trauma and conveyed to the trauma level 1 hospital.
  • Missing valid social security number
  • Not beeing able to give
  • Not a primary assignment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,419 participants (estimated)

Study arms

  • Experimental
    Intervention

    Getting a point-of-care Troponin I analysed, in addition to care according to medical guidelines in EMS

    Diagnostic Test: high sensitivity Troponin I

  • No intervention
    Control

    Getting care according to medical guidelines in EMS

Interventions

  • Diagnostic testhigh sensitivity Troponin I

    Study participants in the intervention group will have the high-sensitivity Troponin I blood test analyzed during emergency medical service (EMS) care using the point-of-care Siemens Atellica® VTLi system. The test result will be documented in the EMS electronic medical record (FRAPP), transmitted along with the ECG, and communicated verbally to the receiving hospital during handover.

06

What researchers measure

Primary outcomes

  1. Time from First Medical Contact to Vascular Access (FMC-to-Access Time)

    Time in minutes from the initial contact with emergency medical services (EMS) to vascular access (arterial puncture) for percutaneous coronary intervention (PCI), representing the time to initiation of the invasive procedure.

    Time frame: From time of first medical contact by EMS to time of vascular access during index PCI procedure, assessed during index hospitalization (typically within 72 hours)

Secondary outcomes

  1. Time from First Medical Contact to Initial ECG (FMC-to-ECG Time)

    Time in minutes from the first contact with emergency medical services (EMS) personnel-defined as the moment EMS arrives at the patient-to completion of the first 12-lead ECG.

    Time frame: From time of initial patient contact by EMS personnel to time of first ECG, assessed during prehospital phase (typically within 1 hour)

  2. Time from First Medical Contact to Emergency Department Admission (FMC-to-ED Admission Time)

    Time in minutes from first EMS contact to arrival and registration at the emergency department.

    Time frame: From time of first medical contact to ED admission, assessed on the day of presentation (typically within 4 hours)

  3. Emergency Department Length of Stay

    Duration in minutes from emergency department registration to transfer or discharge from the ED.

    Time frame: From time of ED admission to ED discharge, assessed during index visit (typically within 24 hours)

  4. Total Hospital Length of Stay

    Duration in minutes from emergency department admission to hospital discharge (from acute care facility).

    Time frame: From ED admission to hospital discharge, assessed during index hospitalization (up to 14 days)

  5. Major Adverse Cardiovascular Events (MACE)

    Composite outcome including the occurrence of any of the following within the specified time frames: myocardial infarction, angina pectoris, all-cause mortality, stroke, or heart failure with reduced ejection fraction (HFrEF).

    Time frame: Assessed at 72 hours and at 30 days from the time of first medical contact, defined as the arrival of emergency medical services (EMS)

  6. Number of Interventions Performed During Acute Care Episode

    Total number of interventions performed per patient from first medical contact through hospital discharge. Interventions may include prehospital treatments (e.g., defibrillation, medication administration) and in-hospital procedures such as diagnostic angiography, percutaneous coronary intervention (PCI), temporary pacing, or surgery.

    Time frame: From the time of first medical contact-defined as the arrival of EMS personnel at the patient's side-through hospital discharge, assessed during the full acute care episode (up to 14 days)

  7. Proportion of participants assigned to in-hospital care

    Proportion of participants assigned to each predefined category of in-hospital care, based on the most resource-intensive setting they were treated in during the index hospitalization. The categories include: * Emergency Department (ED) only * Direct to Percutaneous Coronary Intervention (PCI) * Cardiac Intensive Care Unit (CICU) * Intermediate Care Unit * Other Cardiac Unit * General Care Unit * External Care Institution (e.g., step-down or rehabilitation facility) Unit of Measure: Percentage of participants (%)

    Time frame: From admission to discharge, during index hospitalization (up to 14 days)

  8. Clinical Utility: Sensitivity, Specificity, Negative Predictive Value (NPV), and Positive Predictive Value (PPV).

    Diagnostic performance of prehospital assessment for identifying patients with Myocardial infarction. Includes calculation of sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV), using confirmed diagnosis (ICD-code) at discharge as reference standard.

    Time frame: From the time of EMS assessment (first medical contact) to confirmation of final diagnosis at hospital discharge (typically within 7-14 days)

  9. Incidence of Other Time-Critical Medical Conditions

    Number of participants diagnosed with other time-critical medical conditions within 30 days of first medical contact. These may include but are not limited to: stroke, sepsis, aortic dissection, pulmonary embolism, or major trauma.

    Time frame: Assessed up to 30 days from the time of first medical contact by emergency medical services (EMS)

07

Study locations

1 of 1 sites recruiting
  • Ambulance care in greater Stockholm Ltd. (AISAB)
    Stockholm, Årsta 12040, Sweden
    Recruiting
    • Veronica Vicente, Head of research and inovation, Ass. Professor · Contactveronica.vicente@regionstockholm.se · +46 8 123 120 00
    • Jakob Lederman, Phd · Principal investigator
    • Veronica Vicente, Ass. professor · Sub investigator
    • Sebastian Bjöhle, Doctoral student · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD will not be shared because consent for data sharing was not obtained from participants and data sharing is not feasible due to ethical restrictions

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 12 months is below that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
Jun 6, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07008391
Collaborators
Region Stockholm
Responsible party
Jakob Lederman (PhD, Karolinska Institutet) — Principal investigator
First posted
Jun 6, 2025
Start date
Jun 25, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 2, 2025

Study contacts

Jakob Lederman, PhD
Contact
jakob.lederman@ki.se
0812313189 ext. +46
Sebastian Bjöhle, Doctoral student
Contact
sebastian.bjohle@ki.se
0812312078 ext. +46
Jakob Lederman, PhD
principal investigator · Karolinska Institute, Department of Clinical Science and Education
Veronica Vicente, Docent
study chair · Karolinska Institute, Department of Clinical Science and Education

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion